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6Foreword
The European Union has been legislating on genetically 
modiﬁ ed organisms (GMOs) since the early 1990s. Its objective 
has always been to achieve a high degree of protection of public 
health and the environment in Europe, while simultaneously 
creating a uniﬁ ed market for biotechnology.
Over the last few years, this legislation has been modernised in the light of scientiﬁ c 
developments and public concerns. The new EU legal framework fully entered into 
force in April 2004. It sets out clear, transparent and stringent rules on genetically 
modiﬁ ed food, feed and crops. It is possibly the strictest GMO legislation in the 
world.
Biotechnology has the potential, through agronomically improved crops, to 
deliver better quality food and environmental beneﬁ ts. Indeed, life sciences and 
biotechnology oﬀ er opportunities to address many of the global needs relating to 
health, ageing, food, and the environment and sustainable development.
However, the use of GMOs also raises diﬃ  cult policy issues and regulatory challenges, 
and of course ethical questions. Some applications of biotechnology are widely 
accepted but agri-biotechnology applications, in particular, have provoked broad 
public debate. Opinion on this issue is highly polarised in the EU.
Widespread public support is essential. Ethical and societal implications and 
concerns must be addressed. Having strengthened its legislative framework, 
the EU will continue to explore outstanding issues and take public concerns into 
consideration.
Stavros Dimas
European Commissioner for the Environment
71. EU strategic context
In January 2002, the Commission adopted a Communication outlining a Strategy 
for Europe on Life Sciences and Biotechnology1 , which establishes a strategic 
vision up to 2010. The Communication consisted of two parts, namely policy 
orientations and a plan to transform policy into action in order to exploit the 
development of biotechnologies in a responsible manner. In this context, it also 
detailed the action required from the Commission and other European institutions 
as well as recommending actions from other public and private stakeholders.
The Communication recognises that biotechnology oﬀers potential to address 
global healthcare through innovative approaches, to deliver improved food and 
environmental quality through agronomically enhanced crops and to improve 
non-food uses of crops as sources of industrial feedstocks or new materials. At 
the same time, biotechnology raises particular policy and societal challenges.
Member States have been able to provide input into the Strategy via the 
Competitiveness Council. In addition, the European Commission has reported 
annually on progress with the Strategy and in June 2005 presented its third 
progress report and future orientations2 . 
In line with the timetable set out in the action plan, the Commission has moved 
forward on the speciﬁc regulatory actions within its own jurisdiction in the ﬁeld 
of GMOs. However, it is acknowledged in the progress report that the situation 
regarding European biotechnology and its competitiveness still needs to be 
improved. 
2. Regulatory framework
The EU has legislated on the approval and use of GMOs since the early 
1990s, with the adoption of the ﬁrst directives on the contained use of 
genetically modiﬁed microorganisms (GMMs) and on the deliberate 
release of genetically modiﬁed organisms (GMOs). 
The objective of the EU legislation on GMOs is to protect human health and 
the environment whilst ensuring the free movement of safe genetically 
modiﬁed (GM) products in the EU. Only GMOs and GM food or feed 
products that have been assessed as safe to health and the environment 
are authorised for use in the EU.
(1) Life Sciences and 
Biotechnology – A strategy 
for Europe, COM (2002) 27.
(2) COM (2005) 286 ﬁnal.
8In order to address increasing public concerns and in the light of scientiﬁc 
developments, the European Commission started a full review of the entire 
corpus of GMO legislation in 1999. The aim of the revision was to make the 
Community legislative framework more stringent and transparent, as well 
as to develop traceability and labelling rules.
 
The revised legislative framework on GMOs, which is considered to be one 
of the strictest in the world, has been fully operational since April 2004. Its 
main legal instruments are as follows:
Directive 2001/18/EC on the deliberate release into 
the environment of GMOs  applying to the intentional 
introduction of GMOs3 into the environment without speciﬁc 
containment measures. The Directive covers both releases of GMOs4 
for experimental purposes (e.g. in connection with ﬁeld trials) and 
for commercialisation (for example the cultivation, importation and 
processing or transformation of GMOs into industrial products). 
Regulation (EC) No 1829/2003 on genetically modiﬁed food 
and feed5 , which regulates the placing on the market of GMOs for 
food and feed use, as well as food and feed containing, consisting 
of or produced from GMOs. If one of the uses of a GMO concerns 
food or feed, the applicant may ﬁle a single application for the GMO 
and all its uses (cultivation, processing into industrial products and 
feed use) under this regulation . 
Regulation (EC) No 1946/2003 on transboundary movements 
of genetically modiﬁed organisms6  regulates unintentional 
tansboundary movements of GMOs and exports of GMOs to third 
countries.
Directive 90/219/EEC, as amended by Directive 98/81/EC, on 
the contained use of genetically modiﬁed microorganisms 
(GMMs)7. This Directive regulates research and industrial work 
activities involving GMMs (such as genetically modiﬁed viruses 
or bacteria) under conditions of containment, i.e. in a closed 
environment (e.g. a laboratory) in which contact with the 
environment and the population is avoided. 
Regulation (EC) No 1830/2003 concerning the traceability 
and labelling of genetically modiﬁed organisms and the 
traceability of food and feed products produced from 
genetically modiﬁed organisms and amending Directive 
(3) OJ L106, 17.4.2001, p.1. 
(4) GMOs from now 
on being deﬁned as a 
product containing GMOs 
or consisting of such 
organisms
(5) OJ L268, 18.10.2003, p.1. 
This Regulation amended 
the 1997 Novel Foods 
Regulation (Regulation 
258/97) which governed 
the placing on the market 
of novel food, including 
GM food.
(6) OJ L287, 5.11.2003, p.1.
(7) OJ L117, 8.5.90, p.1.
92001/18/EC8 . As regards GM food and feed, Regulation 1829/2003 
lays down speciﬁ c labelling requirements. 
A considerable number of implementing measures to support operation 
of this framework have also been adopted by Member States over the past 
few years. These include, amongst others, guidelines for risk assessment, 
monitoring, formats for submission of notiﬁ cations, sampling and detection 
and co-existence measures.
2.1.  Release into the environment: Directive 2001/18/EC in detail
In accordance with Directive 2001/18/EC, 
the deliberate release of a GMO into the 
environment means its intentional introduction 
without any precise conﬁ nement measure being 
taken to restrict the contact between this GMO 
and the population or the environment in general. 
Such a release may be carried out for experimental 
purposes or in relation to the placing on the market 
of a GMO.
Experimental releases of GMOs into the 
environment are mainly carried out for the purposes 
of study, research, demonstration and development 
of novel varieties. The behaviour of the GMO in an 
open environment and its interactions with other 
organisms and the environment are studied. The experimental releases are 
subject to the provisions of Part B of Directive 2001/18/EC.
If the results of the experimental release are positive, the company may 
decide to place the GMO on the market, i.e. make it available to third 
parties either free of charge or for a fee. The GMO may be placed on the 
market for purposes of importation, cultivation or transformation into 
diﬀ erent products. The provisions of Part C of Directive 2001/18/EC govern 
the placing on the market of a GMO.
As compared to the previous legislation, Directive 2001/18/EC introduced 
the following principles:
During the authorisation procedure: 
Principles for environmental risk assessment to identify and evaluate 
potential adverse eﬀ ects of the GMO;
Mandatory information to the public;
Principles 
underlying Directive 
2001/18/EC
(8) OJ L268, 18.10.2003, p.24.
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Information to allow the identiﬁcation and detection of GMOs to 
facilitate post-market inspection and control;
The consultation of the European Food Safety Authority (EFSA) to 
be obligatory;
An obligation to inform the European Parliament on decisions to 
authorise the release of GMOs and
The possibility for the Council of the EU to adopt or reject a 
Commission proposal for authorisation of a GMO by qualiﬁed 
majority.
Once the product is authorised and placed on the market:
Mandatory post-market monitoring requirements, including on 
long-term eﬀects associated with the interaction with other GMOs 
and the environment;
A requirement for Member States to ensure labelling and traceability 
at all stages of the placing on the market, according to a Community 
system provided for by Regulation 1830/2003 on traceability;
First approvals for the release of GMOs to be limited to a maximum 
of ten years.
Under Directive 2001/18/EC, a person or a company who wishes to 
introduce a GMO into the environment for experimental purposes must 
ﬁrst obtain written authorisation from the competent national authority 
of the Member State within whose territory the experimental release is to 
take place. 
Following a national procedure, authorisation is granted on the basis of an 
evaluation of potential risks of the GMO for the environment and human 
health. Even though the authorisation would only be applicable in the 
Member State where the notiﬁcation was submitted, the other Member 
States and the European Commission may make observations to be 
examined by the competent national authority.
In the case of a company intending to market a GMO, it must also obtain 
a written authorisation to this end. The GMO placed on the market will 
be deﬁned as a “product consisting of a GMO” (such as GM carnations 
of modiﬁed colour) or a “product containing a GMO” (such as a batch 
containing a mixture of seeds), as appropriate.
In this case, the authorisation procedure involves all Member States, due 
to the fact that once authorised, the product will be allowed to move 
throughout the territory of the EU. The application (called “notiﬁcation”) 
is ﬁrst submitted to the competent national authority of an EU Member 
Authorisation 
for experimental 
purposes
Authorisation for 
placing on the 
market
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State. The notiﬁcation must include a full evaluation of the environmental 
risks. 
The environmental risk assessment will identify and evaluate potential 
adverse eﬀects of the GMO according to a methodology described in Annex 
II to the Directive 2001/18/EC, and including the consideration of direct, 
indirect, immediate or delayed eﬀects, as well as cumulative and long term 
eﬀects. 
The assessment also requires an evaluation of how the GMO was developed 
and examines the potential risks associated with the new gene products 
produced by the GMO (e.g. toxic or allergenic proteins) and the possibility of 
gene transfer (e.g. of antibiotic resistance genes).
The national authority must issue an opinion on the notiﬁcation, in the form 
of an “assessment report”, which may be favourable or unfavourable. In the 
event of an unfavourable report, the company may submit a new notiﬁcation 
for the same GMO to the competent national authority of another Member 
State. This authority may eventually issue a diﬀerent report.
In the event of a favourable opinion for the placing on the market of the 
GMO concerned, the Member State informs the other Member States via the 
European Commission, which examine the assessment report and may issue 
observations and objections.
If there are no objections by other Member States or by the European 
Commission, the competent authority that carried out the original 
assessment authorises the placing on the market of the product. The 
authorised product may then be placed on the market in conformity with 
any conditions set out in the authorisation, which has a maximum duration 
of ten years. The authorisation may be renewed provided certain conditions 
are met, for instance on the basis of the results of the post-market monitoring 
programme. 
 
When objections are raised, the procedure provides for a conciliation phase 
among the Member States, the Commission and the notiﬁer. The objective 
of this phase is to resolve the outstanding questions. 
If at the end of the conciliation phase the objections are maintained, a 
decision must be taken at EU level. The Commission ﬁrst 
asks for the opinion of the European Food Safety Authority 
(EFSA), composed of independent scientists. The Commission 
then presents a draft decision to the Regulatory Committee9 
composed of representatives of the Member States for an 
opinion. 
Environmental risk 
assessment
Standard procedure
Community 
procedure
(9)In accordance with 
Council Decision 
1999/468/EC of 28 June 
1999 laying down the 
procedures  
for the exercise of 
implementing powers 
conferred on the 
Commission. OJ L184, 
17.7.1999, p.23.
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In the event of the Committee giving a favourable opinion by qualiﬁ ed 
majority, the Commission adopts the decision. If not, the draft decision is 
submitted to the Council of Ministers for adoption or rejection by qualiﬁ ed 
majority. In the case of the Council failing to reach qualiﬁ ed majority or not 
acting within three months, the decision would go back to the European 
Commission for adoption.
Following the adoption of the decision, the notiﬁ er may proceed with 
the placing on the market once the written content of the competent 
authority has been received. 
During the notiﬁ cation process, the public is informed and has access to 
the publicly available data on the Internet at: http://gmoinfo.jrc.it, including 
the summary notiﬁ cation, the assessment reports of the competent 
authorities, or the opinion of the European Food Safety Authority (http://
efsa.eu.int). The public has the possibility of providing comments on the 
summary notiﬁ cation and the assessment report.
2.2. Traceability and labelling
Traceability provides the means to trace products 
through the production and distribution lines. The 
general objectives of traceability are to facilitate control 
and veriﬁ cation of labelling claims; targeted monitoring 
of potential eﬀ ects on health and the environment, 
where appropriate; and withdrawal of products that 
contain or consist of GMOs where an unforeseen risk 
to human health or the environment is established.
The Labelling and Traceability Regulation (Regulation 
1830/2003) covers all GMOs that have received EU 
authorisation for their placing on the market, namely all 
products containing or consisting of GMOs, including 
food and feed. Examples include GM seeds and bulk quantities or 
shipments of whole GM grain, such as soybean and maize. The regulation 
also covers food and feed derived from a GMO, as ﬂ our produced from 
genetically modiﬁ ed maize.
The traceability rules oblige the operators concerned, i.e. all persons who 
place a product on the market or receive a product placed on the market 
within the EU, to be able to identify their supplier and the companies to 
which the products have been supplied. 
Information to the 
public
Traceability 
requirements
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1.
The traceability requirement varies depending on whether the product 
consists of or contains GMOs (Article 4) or has been produced from GMOs 
(Article 5). 
In the case of a product consisting of or containing GMOs: 
according to Article 4 of Regulation 1830/2003, operators must 
transmit in writing together with the product: 
an indication that the product – or some of its ingredients – contains 
or consists of GMOs and 
the unique identiﬁer(s) assigned to those GMOs, in the case of 
products containing or consisting of GMOs.
In the case of products produced from GMOs, and according 
to Article 5 of Regulation 1830/2003, operators must transmit in 
writing accompanying the product:
an indication of each of the food ingredients which are produced 
from GMOs; 
an indication of each of the feed materials or additives which are 
produced from GMOs; 
in the case of products for which no list of ingredients exists, an 
indication that the product is produced from GMOs.
In both cases operators must hold the information for a period of ﬁve years 
from each transaction and be able to identify the operator by whom and 
to whom the products have been made available. Each operator must 
keep records and make the information available to the public authorities 
on demand. This practice will reduce the need for sampling and testing of 
products containing a mixture of seeds.
In addition to these traceability provisions, Regulation 1830/2003 also 
sets out labelling requirements for GM products. Labelling informs 
the consumer and user of the product, hence allowing them to make an 
informed choice. 
Generally speaking, for all pre-packaged products consisting of or 
containing GMOs, Regulation 1830/2003 requires that operators indicate 
on a label: “This product contains genetically modiﬁed organisms” or “This 
product contains genetically modiﬁed [(name of organism(s)]”. For non 
pre-packaged products oﬀered to the ﬁnal consumer or to mass caterers 
(restaurants, hospitals, canteens and similar caterers) these words must 
appear on, or in connection with, the display of the product. 
In particular as regards genetically modiﬁed food and feed, Regulation 
1829/2003 lays down speciﬁc labelling requirements10. Genetically 
modiﬁed foods which are delivered as such to the ﬁnal consumer or mass 
Labelling rules
Speciﬁc labelling 
requirements for GM 
food and feed
2.
  (10) See http://www.europa.eu.int/comm/food/food/biotechnology/etiquetage/index_en.htm for more information
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caterers must be labelled, regardless of whether DNA or proteins derived 
from genetic modiﬁcation are contained in the ﬁnal product or not. The 
labelling requirement also includes highly reﬁned products, such as oil 
obtained from genetically modiﬁed maize. 
The same rules apply to animal feed, including any compound feed that 
contains transgenic soya. Corn gluten feed produced from transgenic 
maize must also be labelled, so as to provide livestock farmers with accurate 
information on the composition and properties of feed.
In the production of seeds, food and feed, it is practically impossible to 
achieve products that are 100% pure. Similarly, conventional products may 
be accidentally contaminated by GMOs during cultivation, harvesting, 
storage, transport or processing. Therefore, the legislation has set limits 
above which conventional food and feed must be labelled as products 
consisting of GMOs, containing GMOs or produced from GMOs.
These conventional products “contaminated” by authorised GMOs are not 
however subject to traceability and labelling requirements if they contain 
traces of these GMOs below a limit of 0.9%, provided the presence of this 
material is adventitious or technically unavoidable. This is the case when 
operators demonstrate to the competent authorities that they have taken 
adequate measures to avoid the presence of this material.
In addition, Regulation (EC) No 1829/2003 deﬁnes speciﬁc conditions for 
GMOs that have received a positive assessment by EFSA in terms of safety 
for health and the environment, but not yet formally authorised. The 
regulation allows the presence of these non-authorised GMOs in a food 
or feed up to a maximum of 0.5%, below which labelling and traceability 
will not be enforced. Above 0.5%, it is prohibited to put the product on 
the market.
The Regulation limits the application of this threshold to three years (until 
2007) and provides that a detection method must be publicly available. 
The Commission has published a list of GM material which has not been 
authorised but which has had a favourable scientiﬁc assessment. This list 
may be consulted at the following address: http://www.europa.eu.int/
comm/food/food/biotechnology/gmfood/events_en.pdf
 
2.3. International trade of GMOs
The EU regulatory framework on GMOs takes account of the Cartagena Protocol on 
Biosafety, speciﬁcally as regards the obligations on importers of products in the EU and 
Exemption from 
the traceability 
and labelling 
requirements
0.9% threshold for 
adventitious pres-
ence of authorised 
GMOs
0.5% tolerance level 
for non authorised 
GMOs under speciﬁc 
conditions
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the obligations on exporters of products to third countries. The regulatory system for 
authorising GMOs is consistent with the EU’s international trade commitments and with 
WTO rules: it is clear, transparent and non-discriminatory.
The EU is party to the Cartagena Protocol on Biosafety, which entered into force on 
11 September 2003. This Protocol to UNEP’s Convention on Biological Diversity aims 
at establishing common rules for the transboundary movement of GMOs in order to 
ensure, on a global scale, the protection of biodiversity and of human health. 
The Cartagena Protocol on Biosafety is incorporated into EU legislation through the 
legal framework governing the use of GMOs within the European Union. As presented 
above, the cornerstone of this legal framework is Directive 2001/18/EC. The provisions 
of Directive 2001/18/EC are supplemented by the Regulation on the transboundary 
movements of GMOs (Regulation (EC) No 1946/2003). 
The Regulation (EC) No 1946/2003 was adopted in June 2003 to address speciﬁcally 
export obligations necessary to align the existing regulatory framework with the 
provisions of the Biosafety Protocol. The main features of the Regulation are:
The obligation to notify exports of GMOs intended for deliberate release into 
the environment and secure express consent prior to a ﬁrst transboundary 
movement;
The obligation to provide information to the public and to our international 
partners on EU practices, legislation and decisions on GMOs, as well as on 
accidental releases of GMOs;
A set of rules for the export of GMOs intended to be used as food, feed or for 
processing;
Provisions for identifying GMOs for export.
3. Regulatory challenges
The implementation of the revised regulatory framework has met a number of challenges. 
Diﬃculties are found during the decision making process for authorising the placing 
on the market of GMOs. Moreover, various environmental and safety concerns remain 
despite of the revision of the regulatory framework and have led various Member States 
to invoke safeguard clauses. Last but not least, the diﬃcult development of national 
coexistence measures and the unresolved deﬁnition of seed thresholds hamper a 
comprehensive approach to the cultivation of GMOs.
The division of opinion amongst Member States during the authorisation process is 
leading to the application of the Community procedure to all products notiﬁed under 
Part C of Directive 2001/18/EC as of January 2006. In the absence of the necessary 
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majority at the Council level, the decisions for authorisation go back to the European 
Commission for adoption. This situation has been criticised by various Member States as 
the ﬁ nal decision may go against a majority of them.
 A number of Member States have invoked the so-called “safeguard clause” under 
Article 16 of the previous Directive 90/220/EEC. This clause is also included in Directive 
2001/18/EC, which replaced the aforementioned Directive. The safeguard clause provides 
that where a Member State has justiﬁ able reasons to consider that a GMO, authorised for 
placing on the market, constitutes a risk to human health or the environment, it may 
provisionally restrict or prohibit the use and/or sale of that product on its territory.
The safeguard clause was invoked on nine separate occasions under 
Directive 90/220/EEC, three times by Austria, twice by France, and once 
each by Germany, Luxembourg, Greece and the United Kingdom. The 
scientiﬁ c evidence provided by these Member States as justiﬁ cation 
for their measures was submitted to the Scientiﬁ c Committee(s) of the 
European Union for opinion. In all of these cases, the Committee(s) 
deemed that there was no new evidence which would justify 
overturning the original authorisation decision.
In spite of the repeal of Directive 90/220/EEC, eight of the nine bans 
remained in place (UK withdrew its ban) and were considered under 
the safeguard provision (Article 23) of Directive 2001/18/EC. The GMOs 
in question (Bt 176, T25 and MON 810 maize, Ms1xRf1 and Topas 19/2 
oilseed rape) had been authorised under Directive 90/220 for all uses 
(including cultivation) with the exception of Topas 19/2 (import and 
processing). The Commission examined the additional information 
provided by certain Member States, which has also been reviewed by 
EFSA. In addition, in January 2005, Hungary invoked the safeguard clause in order to 
prohibit the cultivation of MON 810 in its territory. 
In June 2005, the Environment Council reached qualiﬁ ed majority against eight proposals 
to lift the eight bans invoked by ﬁ ve Member States. As a result, DG Environment has 
consulted EFSA again in order to obtain an updated opinion. The Commission now has 
three options, namely to submit either the same or amended proposals back to the 
Council or to submit proposals for adoption through codecision, on the basis of the 
awaited EFSA opinion.
The issues of coexistence measures and seed thresholds, which are closely linked with 
approval and cultivation of GMOs, remain partially unresolved. Pollen ﬂ ow between 
adjacent ﬁ elds is a natural phenomenon. Due to the labelling requirements for GM 
food and feed, this may have economic implications for farmers who want to produce 
traditional plants intended for food.
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Coexistence is about giving farmers the practical choice between conventional, organic 
and GM crop production in compliance with the legal obligations for labelling and purity 
standards. On 5 March 2003, the Commission agreed that it should be up to the Member 
States to develop and implement management measures concerning co-existence, in 
accordance with the subsidiarity principle. 
On 23 July 2003, the Commission adopted a Recommendation (2003/556/EC) on 
guidelines for the development of national strategies and best practices to ensure the 
co-existence of genetically modiﬁ ed crops with conventional and organic farming11 . The 
Recommendation states that approaches to co-existence need to be based on technical 
guidelines and in co-operation with all stakeholders concerned. 
The guidelines are based on experiences with existing segregation practices (e.g. 
in certiﬁ ed seed production); at the same time they ensure 
an equitable balance between the interests of farmers of all 
production types. Furthermore, management measures to ensure 
co-existence should be eﬃ  cient and cost-eﬀ ective, without 
going beyond what is necessary to comply with EU threshold 
levels for GMO labelling. 
They should be speciﬁ c to diﬀ erent types of crop, since the 
probability of admixture varies greatly from one crop to another; 
while for some crops the probability is high (e.g. oilseed rape) for 
others the probability is fairly low (e.g. potatoes). In addition, local 
and regional aspects should be fully taken into account.
Priority should be given to farm-level management measures and to measures aimed 
at co-ordination between neighbouring farms. If it can be demonstrated that these 
measures can not ensure co-existence, regional measures could be considered (e.g. 
restriction on the cultivation of a certain type of GMO in a speciﬁ c region). These 
measures should be justiﬁ ed for each crop and type (e.g. seed and crop production 
separately).
In spite of the guidelines for establishing a framework for co-existence provided in the 
Commission Recommendation, some national measures have been refused by the 
European Commission as disproportionate to their objective and representing a potential 
barrier to free circulation of authorised GMOs. In addition, a number of Member States 
consider the Commission guidelines on coexistence insuﬃ  cient and have demanded 
more precision in terms of guidelines or legislation.
Finally, thresholds below which adventitious traces of GM seeds in conventional seed 
lots do not require labelling have still to be established by the European Commission. 
These threshold levels would address labelling of approved GMOs and should be both 
low enough to serve their purpose and workable and enforceable in practice.
  (11) http://europa.eu.int/comm/agriculture/publi/reports/coexistence2/guide_en.pdf 
18
4. Current situation: overview of GMOs authorised in the EU
Under the “deliberate release” legislation (Directive 2001/18/EC and, previously, Directive 
90/220/EC) numerous GMOs have been approved for diﬀ erent uses, which include 
cultivation, import and processing and feed and food, depending on the speciﬁ c cases. 
Varieties of agricultural products include maize, oil seed rape, soybean and chicory. 
One GM soy and one GM maize were approved for 
use in food products under Directive 90/220/EC 
prior to the entering into force of Regulation (EC) 
No 258/1997 on Novel Foods. Further applications 
for the placing on the market of GM food products 
have been introduced under the Novel Foods 
Regulation and the GM food and feed Regulation 
1829/2003.
Before the entry into force of the Regulation on 
genetically modiﬁ ed food and feed, there was no 
Community legislation governing feed derived 
from GMOs. Such feeds were originally subject 
to Directive 90/220/EEC, and several GM feeds 
were authorised under this Directive. These are 
chieﬂ y maize varieties, rape varieties and one soya 
variety.
Since April 2001 and prior to the entry into force of Regulation (EC) No 1829/2003, 
the Directive 2001/18/EC covered the approval of GMOs for use in feed. Accordingly, 
certain applications submitted under Directive 2001/18/EC before April 2004 have 
been processed and consequently approved under the Directive during the transition 
period.
Products authorised under Regulation (EC) No 1829/2003 on GM food and feed are 
entered into a public register, which is available at: http://europa.eu.int/comm/food/
dyna/gm_register/index_en.cfm. 
As of January 2006, ﬁ ve products have been approved, under the Directive 2001/18/
EC, for import and processing and in some cases also use in animal feed. These 
products are MON 863, NK 603, MON 863 x MON 810 and 1507 maize and GT73 oilseed 
rape. Eight applications for the placing on the market of GMOs (e.g. maize, oil seed rape, 
cotton, carnation and potato) for authorisation under Directive 2001/18/EC are pending. 
Several applications have a scope restricted to import and processing, while others also 
include cultivation as a requested use.  
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Finally, the EU legislation on seeds12  concerning the marketing of seed varieties of 
agricultural plant and vegetable species requires that GM varieties have to be authorised 
in accordance with the Directive 2001/18/EC, before they are included in the Common 
Catalogue and marketed in the EU. So far, 31 GM varieties derived from MON 810 maize 
are inscribed in the Common Catalogue of Varieties of Agricultural Plant Species. If the 
seed is intended for use in food, it also has to be authorised in accordance with the GM 
food and feed Regulation.
5. Research and development in support of biotechnology
Life sciences and biotechnology can provide a major contribution to 
strengthening the European Union’s competitiveness. The life sciences 
and biotechnology industry have the potential to be leading areas of 
science, industry and employment over the coming decades. As a leading 
edge technology, they can contribute to the modernisation of Europe’s 
industrial base and to the creation of growth and new jobs.
The European Commission has been supporting biotechnology through 
its research programmes over the last years. Since 1985 the European 
Commission has been ﬁ nancing research projects focusing on the safety 
of GMOs. A project funded under the 5th Framework Programme for 
Research (FP5), involving more than forty-ﬁ ve research centres, concluded 
that GMO crops evaluated were as safe as conventionally grown crops.
The 6th Framework Programme for Research (FP6) has provided a major 
incentive for research in the area of biotechnology. FP6 continues to give a 
strong impetus, in particular in terms of critical mass of human and ﬁ nancial 
resources, sharing of knowledge and facilities, strengthening of scientiﬁ c excellence, 
coordination of national activities and support for EU policies. A number of projects have 
received a total contribution of over EUR36 million, addressing risk assessment methods 
and coexistence challenges.
On 6 April 2005, the Commission adopted a proposal for the Seventh EC Research 
Framework Programme 2007-2014 (FP7). Life sciences and biotechnology research 
will remain a priority in FP7. The proposal includes further research to support the 
implementation of the regulatory framework on GMOs under its theme “Agriculture, 
food and biotechnology”.
The EU also provides scientiﬁ c support in relation to GMOs through its in-house Joint 
Research Centre (JRC). The JRC is undertaking research on underlying mechanisms 
for integrating foreign genes into host plants, and evaluating their long-term stability. 
  (12) Notably Directives 2002/53/EC and 2002/55/EC
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Research is also carried out to develop detection and quantiﬁ cation methods for the 
presence of GMOs in raw materials, ingredients and ﬁ nal products. The JRC co-ordinates 
as well the European Network of GMO Laboratories, which brings together more than 
forty-ﬁ ve EU control laboratories to share information and methods for sampling, 
detection, identiﬁ cation and quantiﬁ cation of GMOs.
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6.  Conclusion
The implementation of the revised regulatory framework started in April 2004, which 
provides the Commission with limited experience to date. Throughout 2004 and 2005, 
the European Commission has progressed with the pending decisions concerning the 
placing on the market of new genetically modiﬁed products and the lifting of national 
safeguard clauses through comitology procedures, in accordance with the provisions of 
the EU legislation on GMOs. 
In its most recent orientation debate on 22 March 2005, the Commission conﬁrmed its 
full conﬁdence in the existing regulatory framework on GMOs and concluded that it 
would continue to comply fully with its legal obligations and proceed with the approval 
of pending authorisations, as appropriate. However, in spite of notable improvements in 
the regulatory framework, public and political concerns about GMOs still exist.
Reports concerning the implementation and operation of the regulatory framework, as 
required by Directive 2001/18/EC, Regulation (EC) No 1829/2003 and Regulation (EC) No 
1830/2003, are being prepared by the Commission for adoption in 2006. The Commission 
is compiling a report on the experience gained in the Member States concerning the 
implementation of measures to address co-existence. 
In 2006 as well, a report on the implementation of Regulation (EC) No 1946/2003 will 
start to be compiled from information to be submitted by the Member States. Some 
of these reports may feed a debate foreseen at the Environment Council in 2006, in 
order to discuss constraints and opportunities related to GMO technology, as well as 
diﬃculties found in the decision-making process.
As part of the implementation of the Strategy on Life Sciences and Biotechnology, the 
Commission will carry out a comprehensive assessment and cost-beneﬁt analysis of the 
consequences, opportunities and challenges that applications of modern biotechnology 
present for Europe in terms of economic, social and environmental aspects. The results 
of this study will contribute to a midterm review of the Strategy in 2006-2007.
The Commission will continue its eﬀorts to address the outstanding challenges, which 
could increase cooperation in decision making and ultimately result in a wider consensus 
amongst institutions, Member States and other stakeholders. In parallel, the political 
debate foreseen in 2006 and the various technical reports expected in 2006 and 2007 
will contribute to obtaining a more comprehensive picture of the implementation of the 
regulatory framework on GMOs and of the challenges ahead. 
DG Environment biotechnology: http://europa.eu.int/comm/environment/biotechnology/index_en.htm
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Further reading:
• GMO Products approved under Directive 90/220/EEC as of March 2001
See http://europa.eu.int/comm/environment/biotechnology/authorised_prod_1.htm
• GMO products authorised under Directive 2001/18/EC 
See http://europa.eu.int/comm/environment/biotechnology/authorised_prod_2.htm 
• GMO products – pending notiﬁcations under Directive 2001/18/EC
See http://europa.eu.int/comm/environment/biotechnology/pending_products.htm 
• Genetically modiﬁed (GM) Foods and Feeds authorised in the European Union
For genetically modiﬁed (GM) food authorised in the EU under the Novel Food Regulation (EC) No. 258/97 
see:
http://europa.eu.int/comm/food/food/biotechnology/authorisation/258-97-ec_authorised_en.pdf
For GMOs authorised for feed use in the EU in accordance with Directives 90/220/EEC and 2001/18/EC see:
http://europa.eu.int/comm/food/food/biotechnology/authorisation/2001-18-ec_authorised_en.pdf
 
For applications for authorisation of genetically modiﬁed (GM) foods submitted under the Novel Food 
Regulation (EC) No. 258/97 see:
http://europa.eu.int/comm/food/food/biotechnology/authorisation/258-97-ec_pending_authos_en.pdf
For feed consisting of or containing GMOs notiﬁed under Directive 2001/18/EEC pending authorisation in the 
EU see:
http://europa.eu.int/comm/food/food/biotechnology/authorisation/2001-18-ec_pending_authos_en.pdf
For applications for authorisation of genetically modiﬁed food and feed submitted under Regulation (EC) No 
1829/2003 on genetically modiﬁed food and feed see:
http://www.efsa.eu.int/science/gmo/gm_ﬀ_applications/catindex_en.html
• GMO Products invocation of Article 16 under Directive 90/220/EEC and Article 23 of Directive 
2001/18/EC (safeguard clauses)
See http://europa.eu.int/comm/environment/biotechnology/safeguard_clauses.htm 
 
Useful links:
• The European Commission Biotechnology website: http://europa.eu.int/comm/biotechnology/
• The Food Safety Website: http://europa.eu.int/comm/food/food/biotechnology/index_en.htm
• DG Sanco Register to food and feed: http://www.europa.eu.int/comm/food/dyna/gm_register/ 
    index_en.cfm
• The Biotechnology and GMOs information website: http://gmoinfo.jrc.it/default.asp
• The EFSA website: http://www.efsa.eu.int/index_en.html
• The GMO Methods Database: http://biotech.jrc.it/methodsdatabase.htm
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